Search
for
Sort by
Research 121–150 of 1000+
- Under Development JAK Inhibitors for Dermatologic Diseases
- New small molecules in dermatology: for the autoimmunity, inflammation and beyond
- Use of Jak Inhibitors in the Treatment of Alopecia Areata
- Clinical evidence for JAK inhibition in alopecia areata: A comprehensive review
- Which is the ideal JAK inhibitor for alopecia areata – Baricitinib, tofacitinib, ritlecitinib or ifidancitinib - Revisiting the immunomechanisms of the JAK pathway
- Emerging Topical and Systemic JAK Inhibitors in Dermatology
- The Changing Landscape of Alopecia Areata: The Therapeutic Paradigm
- JAK Inhibitors for Treatment of Alopecia Areata
- Inibidores das Janus Associated Kinases na Terapêutica Farmacológica
- Current Trends and Emerging Paradigms in the Treatment of Alopecia Areata
- JAK-Inhibitors Beyond the Label: Emerging Applications in Dermatology
- Dermatologic Comorbidities Associated with Atopic Dermatitis Towards a Shared Therapeutical Approach: A Narrative Review
- Evaluating Current and Emergent JAK Inhibitors for Alopecia Areata: A Narrative Review
- Nouvelles thérapeutiques dans la prise en charge de l’alopécie androgénétique
- Hair Follicle Reconstruction and Stem Cells
- Precision therapeutics in non-scarring alopecia: a systemic genomic and pathway-based framework for targeted interventions
- Alopecia areata: from immunopathogenesis to emerging therapeutic approaches
- Modern Management Approaches for Alopecia Areata
- Identifying the Target Cells and Mechanisms of Merkel Cell Polyomavirus Infection
- Ritlecitinib in Alopecia Areata: A 24‐Week Real‐World Experience Contrasting JAK Inhibitor‐Naïve and JAK Inhibitor‐Experienced Patients
- Moving Beyond Boundaries: Utilization of Longitudinal Exposure–Response Model for Bounded Outcome Score to Inform Decision Making in the Accelerated Drug Development Paradigm
- Case Report: Reversal of Long-Standing Refractory Diffuse Non-Scarring Alopecia Due to Systemic Lupus Erythematosus Following Treatment With Tofacitinib
- Real‐world experience and long‐term evaluation of tofacitinib in refractory alopecia areata: A prospective, open‐label, single‐center study in Asian Arab population
- Refractory alopecia in lupus treated with tofacitinib — a case-based review
- Advances in the mechanism and new therapies of alopecia areata
- Overview of alopecia areata for managed care and payer stakeholders in the United States
- Current Treatments for Alopecia Areata
- The Possible Role of Antibodies in Alopecia: A Narrative Review
- “<i>Nomen Omen</i>: The Myth of God Janus”
- The JAK/STAT signaling pathway: from bench to clinic